EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pharmena's enterprise value is zł47.11 Mil.
Pharmena's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was zł9.84 Mil. Therefore, Pharmena's EV-to-Revenue for today is 4.79.
The historical rank and industry rank for Pharmena's EV-to-Revenue or its related term are showing as below:
WAR:PHR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.26 Med: 8.57 Max: 20.57
Current: 4.79
During the past 13 years, the highest EV-to-Revenue of Pharmena was 20.57. The lowest was 1.26. And the median was 8.57.
WAR:PHR's EV-to-Revenue is ranked better than 63.58% of 1038
companies
in the Biotechnology industry
Industry Median: 8.115
vs WAR:PHR: 4.79
As of today (2024-05-29), Pharmena's stock price is zł6.08.
Pharmena's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was zł0.88. Therefore, Pharmena's PS Ratio for today is 6.89.
Pharmena EV-to-Revenue Historical Data
The historical data trend for Pharmena's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharmena's EV-to-Revenue
For the Biotechnology subindustry, Pharmena's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmena's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmena's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pharmena's EV-to-Revenue falls into.
Pharmena's current Enterprise Value is zł47.11 Mil.
Pharmena's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł9.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmena's share price for today is zł6.08.
Pharmena's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmena EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Pharmena's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WAR:PHR has been successfully added to your 